Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells $1,986,613.45 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $29.35, for a total transaction of $1,986,613.45. Following the sale, the chief operating officer now directly owns 706,872 shares of the company’s stock, valued at $20,746,693.20. The trade was a 8.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Melissa Baird also recently made the following trade(s):

• On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The stock was sold at an average price of $31.01, for a total value of $2,653,246.61.
• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $21.04, for a total value of $1,236,100.00.

Hims & Hers Health Stock Down 0.0 %

HIMS stock opened at $30.89 on Friday. Hims & Hers Health, Inc. has a 52-week low of $8.51 and a 52-week high of $35.02. The firm has a market cap of $6.75 billion, a P/E ratio of 70.20 and a beta of 1.31. The company’s 50-day simple moving average is $28.22 and its 200-day simple moving average is $22.18.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.04) earnings per share. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after purchasing an additional 206,078 shares in the last quarter. Geode Capital Management LLC lifted its stake in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after buying an additional 883,230 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after buying an additional 218,566 shares during the last quarter. Finally, Verition Fund Management LLC increased its stake in Hims & Hers Health by 15.0% during the 3rd quarter. Verition Fund Management LLC now owns 645,731 shares of the company’s stock worth $11,894,000 after buying an additional 84,316 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on HIMS. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Piper Sandler increased their price objective on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. TD Cowen reaffirmed a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Citigroup downgraded shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price target for the stock from $24.00 to $25.00 in a report on Friday, January 10th. Finally, BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.